Robert Berman, Chief Medical Officer at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 69,410 shares at $30.68 ($2.1M) on 2018-03-12, disclosed to the SEC on 2018-03-14.
Open-market sale of $2.1M BHVN by Chief Medical Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.06 | 6,410 | $193K | 9.2% |
| 2 | $30.06 | 6,410 | $193K | 9.2% |
| 3 | $30.06 | 25,640 | $771K | 36.9% |
| 4 | $30.06 | 25,640 | $771K | 36.9% |
| 5 | $30.68 | 2,360 | $72K | 3.5% |
| 6 | $30.68 | 2,360 |
| $72K |
| 3.5% |
| 7 | $30.68 | 590 | $18K | 0.9% |
| Total | $30.11 avg | 69,410 | $2.1M | 100% |
| Filing → |
| BHVN | SELL | 2020-06-22 | $9.3M | — | Filing → |
| BHVN | SELL | 2019-12-31 | $13.3M | — | Filing → |
| BHVN | BUY | 2019-06-28 | $106K | — | Filing → |